Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.2021212306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The X-Age Project to construct a Chinese aging clock.
Nat Aging
September 2025
Aging Biomarker Consortium (ABC), Beijing, China.
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age-related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual's physiological and molecular state, across diverse Chinese cohorts.
View Article and Find Full Text PDFAutomated Literature Screening for Hepatocellular Carcinoma Treatment Through Integration of 3 Large Language Models: Methodological Study.
JMIR Med Inform
September 2025
Department of Hepatobiliary and Vascular Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis.
Objective: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines.
Artificial Intelligence-based Liver Volume Measurement Using Preoperative and Postoperative CT Images.
Curr Med Imaging
August 2025
Department of Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Introduction: Accurate liver volumetry is crucial for hepatectomy. In this study, we developed and validated a deep learning system for automated liver volumetry in patients undergoing hepatectomy, both preoperatively and at 7 days and 3 months postoperatively.
Methods: A 3D U-Net model was trained on CT images from three time points using a five-fold cross-validation approach.
Electronic decision aids enhance management of primary care patients with steatotic liver disease: Proof of concept pilot study.
Hepatol Commun
September 2025
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: The approach to appropriate risk stratification for metabolic dysfunction-associated steatotic liver disease (MASLD) is variable, and the adoption of non-invasive liver disease assessments in clinical practice is suboptimal. In this study, we implemented an electronic decision support tool for primary care patients with MASLD to assess its influence on linkage to care.
Methods: We performed a prospective, before-and-after pilot study in which post-implementation providers were presented with an electronic decision aid automating non-invasive liver disease assessments with the Fibrosis-4 score and providing individualized, guideline-directed recommendations.
Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy.
Med Phys
August 2025
QuantIF AIMS, University of Rouen, Rouen, France.
Background: Patient-specific dosimetry in radiopharmaceutical therapy (RPT) offers a promising approach to optimize the balance between treatment efficacy and toxicity. The introduction of 360° CZT gamma cameras enables the development of personalized dosimetry studies using whole-body single photon emission computed tomography and computed tomography (SPECT/CT) data.
Purpose: This study proposes to validate the collapsed-cone superposition (CCS) approach against Monte Carlo (MC) simulations for whole-body dosimetry of [177Lu]Lu-PSMA-617 therapy in patients with metastatic castration resistant prostate cancer (mCRPC).